S&P Futures
4,264.00 -12.75 (-0.30%) Dow Futures
33,888.00 -75.00 (-0.22%) Nasdaq Futures
13,442.75 -50.50 (-0.37%) Russell 2000 Futures
1,985.70 -3.40 (-0.17%) Crude Oil
88.11 0.00 (0.00%) Gold
1,776.80 +0.10 (+0.01%)
DWS High Income Fund (KHYAX)
| Previous Close | 4.3800 |
| YTD Return | -7.35% |
| Expense Ratio (net) | 0.00% |
| Category | High Yield Bond |
| Last Cap Gain | 0.00 |
| Morningstar Rating | ★★★★★ |
| Morningstar Risk Rating | N/A |
| Sustainability Rating | N/A |
| Net Assets | 670.63M |
| Beta (5Y Monthly) | N/A |
| Yield | N/A |
| 5y Average Return | N/A |
| Holdings Turnover | N/A |
| Last Dividend | 0.02 |
| Average for Category | N/A |
| Inception Date | Jan 26, 1978 |
- PR Newswire
UFC® AND THORNE ANNOUNCE MULTI-YEAR EXTENSION OF PARTNERSHIP
UFC®, the world's premier mixed martial arts organization, and Thorne Health Tech, Inc. ("Thorne HealthTech" or "Thorne") (NASDAQ: THRN), a leader in developing innovative solutions for a personalized approach to health and wellbeing, today announced a multi-year extension of their global marketing partnership. Thorne remains the Official Sports Performance Nutrition Partner of UFC and an official partner of the UFC Performance Institute®, the world's first Mixed Martial Arts (MMA) multi-discipl
- CNW Group
Tetra Bio-Pharma Signs License Agreement with Thorne for a Prebiotic Dietary Supplement
Tetra Bio-Pharma Inc ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development, today announced it has signed a Licensing Agreement with Thorne Health Tech, Inc. ("Thorne HealthTech" or "Thorne") (NASDAQ: THRN), a leader in developing innovative solutions for a personalized approach to health and wellbeing, for the commercialization of its patent protected prebiotic dietary supplement in the U.S. market. The Agreement will incl
